Sanjay Popat, BSc MBBS FRCP PhD, from the Royal Marsden Hospital, London, UK, discusses highlights from the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The PACIFIC study (NCT02125461) was a large, randomised Phase III trial investigating the use of durvalumab in non-small cell lung cancer patients who had completed concomitant chemo-radiotherapy. This trial had a combined endpoint of progression free and overall survival, with durvalumab being significantly superior to placebo. Durvalumab could be considered as consolidation therapy for patients completing thoracic chemoradiotherapy.
